2020
In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso
Lingani M, Bonkian L, Yerbanga I, Kazienga A, Valéa I, Sorgho H, Ouédraogo J, Mens P, Schallig H, Ravinetto R, d’Alessandro U, Tinto H. In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal 2020, 19: 8. PMID: 31906948, PMCID: PMC6945612, DOI: 10.1186/s12936-019-3089-z.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsArtesunateBurkina FasoChildChild, PreschoolDrug CombinationsDrug Therapy, CombinationFemaleHumansInfantInhibitory Concentration 50LumefantrineMalaria, FalciparumMaleMass Drug AdministrationPlasmodium falciparumTreatment FailureTreatment OutcomeConceptsFirst-line treatmentArtemether-lumefantrineUncomplicated malariaFalciparum malariaTreatment failureOverall adverse event incidenceUncomplicated Plasmodium falciparum malariaEx vivo efficacyUnadjusted cure rateAdverse event incidenceUncomplicated falciparum malariaPlasmodium falciparum malariaP. falciparum susceptibilityMalaria-endemic areasEx vivo susceptibilityMass drug administrationP. falciparum isolatesEx vivo analysisAL armASAQ armOpen labelPrimary endpointRecurrent parasitaemiaEvent incidenceTreatment arms
2015
Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso
Tahita M, Tinto H, Yarga S, Kazienga A, Traore/Coulibaly M, Valea I, Van Overmeir C, Rosanas-Urgell A, Ouedraogo J, Guiguemde R, van Geertruyden J, Erhart A, D’Alessandro U. Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso. Malaria Journal 2015, 14: 251. PMID: 26088768, PMCID: PMC4474342, DOI: 10.1186/s12936-015-0769-1.Peer-Reviewed Original ResearchMeSH KeywordsAntimalarialsBurkina FasoDrug ResistanceFemaleHumansInhibitory Concentration 50Malaria, FalciparumParasitic Sensitivity TestsPlasmodium falciparumPregnancySeasonsConceptsPregnant womenAnti-malarial drugsDrug sensitivity profilesParasite densityAnti-malarial drug susceptibilityDifferent drug sensitivity profilesUncomplicated Plasmodium falciparum malariaTreatment Efficacy TrialInfected pregnant womenArtemisinin-based combinationsPlasmodium falciparum malariaChloroquine-resistant isolatesHistidine-rich protein-2 assayPlasmodium falciparum isolatesGeometric mean IC50Low parasite densitiesP. falciparum parasitesTreatment of malariaFalciparum malariaRecurrent infectionsMean IC50Efficacy trialsFalciparum isolatesMethodsThe studyResistant parasites
2014
Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change
Tinto H, Bonkian L, Nana L, Yerbanga I, Lingani M, Kazienga A, Valéa I, Sorgho H, Kpoda H, Guiguemdé T, Ouédraogo J, Mens P, Schallig H, D’Alessandro U. Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change. Malaria Journal 2014, 13: 207. PMID: 24885950, PMCID: PMC4049403, DOI: 10.1186/1475-2875-13-207.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntimalarialsBurkina FasoChildChild, PreschoolFemaleHumansInfantInhibitory Concentration 50Malaria, FalciparumMaleParasitic Sensitivity TestsPlasmodium falciparumConceptsP. falciparum sensitivityVivo studiesFirst-line treatmentPlasmodium falciparum fieldAnti-malarial drugsEx vivo studyDrug sensitivity profilesDHA-PPQChloroquine resistanceIC50 valuesPartner drugsDrug efficacy testsDrug measurementsInhibitory concentration valuesMonodesethylamodiaquinePiperaquineEfficacy of ALHigher IC50 valuesPlasmodium falciparumDihydroartemisininFive yearsCellular proliferationDrugsRecent reportsLumefantrine